Genzyme's patient focus led us to pioneer therapeutic treatments for rare genetic diseases known as lysosomal storage disorders (LSDs). We now have three marketed LSD products, and a fourth has entered the regulatory approval process. Our continued success is based on our ability to meet medical needs and our global commitment to patient care.

Two-year-old Yuua has been diagnosed with Fabry disease, but his twin brother, Toshia, does not have this condition. Their mother and grandmother have also been diagnosed, and the grandmother has begun Fabrazyme therapy. Fabrazyme was approved in Japan in 2004.